Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Free Report) – Stock analysts at HC Wainwright reduced their Q3 2026 earnings per share (EPS) estimates for shares of Phio Pharmaceuticals in a research report issued on Wednesday, August 26th. HC Wainwright analyst M. Keller now expects that the company will earn ($0.37) per share for the quarter, down from their prior forecast of ($0.34). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Phio Pharmaceuticals’ current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Phio Pharmaceuticals’ Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($1.47) EPS and FY2027 earnings at ($0.77) EPS.
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Phio Pharmaceuticals in a report on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $14.00.
Phio Pharmaceuticals Price Performance
Shares of NASDAQ:PHIO opened at $1.12 on Friday. The business has a 50-day moving average of $1.05 and a two-hundred day moving average of $1.13. The firm has a market capitalization of $13.01 million, a PE ratio of -0.87 and a beta of 0.82. Phio Pharmaceuticals has a 12 month low of $0.81 and a 12 month high of $4.19.
Phio Pharmaceuticals (NASDAQ:PHIO – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.36).
Institutional Inflows and Outflows
A hedge fund recently raised its position in Phio Pharmaceuticals stock. Geode Capital Management LLC lifted its stake in Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Free Report) by 60.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 92,638 shares of the company’s stock after buying an additional 34,732 shares during the period. Geode Capital Management LLC owned approximately 0.86% of Phio Pharmaceuticals worth $97,000 as of its most recent SEC filing. 57.31% of the stock is currently owned by institutional investors.
Phio Pharmaceuticals Company Profile
Phio Pharmaceuticals, Inc (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology.
Phio’s TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion.
Featured Articles
- Five stocks we like better than Phio Pharmaceuticals
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
